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Loss of SPARC-mediated VEGFR-1
suppression after injury reveals a novel
antiangiogenic activity of VEGF-A
Miho Nozaki,1 Eiji Sakurai,1,2 Brian J. Raisler,1,3 Judit Z. Baffi,1 Jassir Witta,4 Yuichiro Ogura,2
Rolf A. Brekken,5 E. Helene Sage,6 Balamurali K. Ambati,7 and Jayakrishna Ambati1,3
1Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, USA. 2Department of Ophthalmology,
Nagoya City University Medical School, Nagoya, Japan. 3Department of Physiology and 4Department of Internal Medicine, University of Kentucky,
Lexington, Kentucky, USA. 5Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 6Hope Heart Program,
Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA. 7Department of Ophthalmology, Medical College of Georgia, Augusta, Georgia, USA.

VEGF-A promotes angiogenesis in many tissues. Here we report that choroidal neovascularization (CNV) incited by injury was increased by excess VEGF-A before injury but was suppressed by VEGF-A after injury. This
unorthodox antiangiogenic effect was mediated via VEGFR-1 activation and VEGFR-2 deactivation, the latter via
Src homology domain 2–containing (SH2-containing) tyrosine phosphatase-1 (SHP-1). The VEGFR-1–specific
ligand placental growth factor-1 (PlGF-1), but not VEGF-E, which selectively binds VEGFR-2, mimicked these
responses. Excess VEGF-A increased CNV before injury because VEGFR-1 activation was silenced by secreted
protein, acidic and rich in cysteine (SPARC). The transient decline of SPARC after injury revealed a temporal
window in which VEGF-A signaling was routed principally through VEGFR-1. These observations indicate that
therapeutic design of VEGF-A inhibition should include consideration of the level and activity of SPARC.
Introduction
VEGF-A, which signals through the receptor tyrosine kinases
VEGFR-1 and VEGFR-2, plays a dominant role in physiologic and
pathologic angiogenesis, with VEGFR-2 implicated as its principal proangiogenic transducer. The function of VEGFR-1 is more
nebulous. In vitro studies in porcine aortic (1) or human umbilical
vein endothelial cells (2, 3) demonstrate that VEGFR-1 repressed
VEGFR-2–mediated cell proliferation through active signaling.
Deletion of Vegfr1 in mice results in embryonic lethality due to
endothelial overcrowding and disorganized vasculature (4). However, vascular development is grossly unaffected in mice with a
deletion of the VEGFR-1 kinase domain (Veg fr1 tk–/–) (5), which
suggests that VEGFR-1 subserves a negative role in embryogenesis
by acting as a trap that modulates endogenous VEGF-A levels. In
pathologic angiogenesis, however, conflicting data about VEGFR-1
function have emerged from studies demonstrating that it both
amplifies (6, 7) and antagonizes (8) neovascularization. VEGFR-1
signaling therefore appears to be both cell/tissue specific and context/stage dependent.
Choroidal neovascularization (CNV) is the principal cause
of blindness in patients with age-related macular degeneration
(AMD), a condition responsible for vision loss in 25–30 million
people worldwide in total (9). VEGF-A is present in CNV membranes surgically excised from patients with AMD (10), and pharmacological inhibition of VEGF-A decreases experimental laserNonstandard abbreviations used: ALK1, activin receptor–like kinase 1; AMD,
age-related macular degeneration; BMOV, bis(maltolato)oxovanadium(IV); CNV,
choroidal neovascularization; PAI-1, plasminogen activator inhibitor type I; PlGF-1,
placental growth factor-1; PTP, protein tyrosine phosphatase; RPE, retinal pigmented epithelium; SH2, Src homology domain 2; SHP-1, SH2-containing tyrosine
phosphatase-1; SPARC, secreted protein, acidic and rich in cysteine.
Conflict of interest: J. Ambati is listed on an initial patent filing by the University of
Kentucky describing these findings.
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induced CNV (11). These data are the bases for current clinical
trials of anti–VEGF-A therapy in patients with AMD.
However, the precise role of VEGF-A in CNV remains unclear.
Whereas subretinal injection of viral vectors encoding VEGF-A leads
to retinal pigmented epithelium (RPE) overexpression of VEGF-A
and subsequent CNV (12), increased production of VEGF-A directed by RPE-specific promoters, such as RPE65 or VMD2, does not
produce CNV (13, 14). However, enhancement of VEGF-A coupled
with subretinal injection of null viral vector induced CNV (14), suggesting that increased VEGF-A alone is insufficient to induce CNV
without concomitant mechanical trauma or immune deviation. A
clinical trial of an anti–VEGF-A aptamer (pegaptanib) in CNV demonstrated an inverse dose response in visual outcome (15). Further,
although the lowest dose decreased the rate of vision loss, it did not
prevent an increase in CNV lesion size.
It is now appreciated that activities of VEGF-A and other cytokines
are influenced by the interaction of cells with the ECM. Matricellular proteins regulate cell-ECM communication and thereby can
influence many remodeling events, including angiogenesis (16). We
focused on the matricellular protein SPARC (secreted protein, acidic and rich in cysteine) because it has been reported to decrease the
stimulatory activity of VEGF-A on endothelial cell proliferation, in
part by its abrogation of VEGFR-1 phosphorylation (17).
Results
VEGF-A inhibits CNV via VEGFR-1. We tested the effect of injecting
VEGF-A into the vitreous cavity of mice after laser injury. This
injury fractures Bruch membrane, the ECM between the RPE and
choroid, the highly vascular tissue beneath the RPE, and triggers
proliferation of choroidal endothelial cells that subsequently
migrate through these fractures, resulting in CNV (18, 19). Intravitreous injection of VEGF-A (0.02–0.95 pmol), either immediately following or 1 day after laser injury, decreased the volume
of CNV in a dose-dependent fashion at both 1 (Figure 1, A and B)
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Figure 1
VEGFR-1 ligands suppressed CNV. (A) Stacked
confocal image of representative laser-induced
CNV lesions in PBS-treated eyes were larger
than in VEGF-A–treated (0.29 pmol) or PlGF-1–
treated (4.3 pmol) eyes and smaller than in
VEGF-E–treated (0.34 pmol) eyes. Scale bars:
100 μm. (B) PBS treatment alone did not reduce
CNV, and VEGF-A (0.1 pmol) reduced CNV
regardless of the treatment of the fellow eye.
n = 15–46 per data point. #P < 0.05 compared
with corresponding uninjected or PBS-treated
groups. (C) VEGF-A (red; n = 38–46 per data
point) and PlGF-1 (blue; n = 18 per data point)
reduced CNV at 1 week after injury in a dosedependent fashion. VEGF-E (purple) and PlGF-1
together (single data point depicted as dotted
line) suppressed CNV similar to PlGF-1 alone.
n = 12 per data point. VEGF-E increased
CNV. n = 12. *P < 0.01, #P < 0.05 compared
with PBS; §P < 0.01 compared with VEGF-E;
P > 0.90 compared with PlGF-1. (D) CNV inhibited by CoCl2 (0.77 nmol) was abrogated by
anti–VEGF-A antibody (6.7 fmol) but not by control goat IgG (6.7 fmol). Anti–VEGF-A antibody
modestly reduced CNV compared with goat
IgG. *P < 0.01 compared with control (PBS).
#P < 0.05 compared with goat IgG. n = 18–24
per data point.

and 2 weeks (data not shown) after laser injury. CNV volume in
eyes injected with vehicle (PBS) alone did not differ significantly
from that in the uninjected fellow eyes; further, CNV volume in
eyes treated with VEGF-A did not depend on whether the fellow
eye was uninjected or treated with PBS or VEGF-A (Figure 1C).
To test whether endogenous VEGF-A would induce similar
effects, we injected CoCl2, which increases VEGF-A expression.
Intravitreous injection of CoCl2 (0.77 nmol) 1 day after laser injury
decreased the volume of CNV compared with PBS or no injection;
this inhibition was abrogated by neutralizing anti–VEGF-A antibody but not by isotype control IgG (Figure 1D). We confirmed
the functional specificity of this anti–VEGF-A antibody by demonstrating that it modestly inhibited CNV, in comparison with
control IgG, consistent with previous reports of VEGF-A blockade
(11). Although CoCl2 can induce pleiotropic effects in cells, reversal
of the antiangiogenic effect by specific neutralization of VEGF-A
confirms its involvement in suppressing CNV. Because hypoxia
has been speculated to be involved in CNV (reviewed in ref. 20),
the effects of CoCl2 might be pathophysiologically relevant.
Because VEGF-A binds both VEGFR-1 and VEGFR-2, we tested
the effects of placental growth factor-1 (PlGF-1), a VEGFR-1–specific ligand (21), and VEGF-E, a VEGFR-2–specific ligand (22).
Intravitreous injection of PlGF-1 (0.03–43.1 pmol) resulted in similar dose-dependent suppressive effects on CNV, whereas VEGF-E
(0.11–1.14 pmol) did not (Figure 1B). Inhibition of CNV by VEGF-A
or CoCl2 was abolished by neutralizing antibody against VEGFR-1
(40 pmol; IC50 = 13.3–53.3 nM) but not by anti–VEGFR-2 (1.7 pmol;
IC50 = 0.7–2 nM) or by isotype control antibody (40 pmol) (Figure

2A). At the doses used, intravitreous injection of anti–VEGFR-2
antibody modestly reduced CNV, confirming a prior report (23);
however, intravitreous injection of anti–VEGFR-1 antibody did
not reduce CNV, a result different from a prior report of systemic
VEGFR-1 blockade (24) (discussed below). The modest increase in
CNV induced by VEGF-E was blocked by anti–VEGFR-2 antibody
but not anti–VEGFR-1 or isotype control antibody, confirming the
specificity and effectiveness of these doses (Figure 2A). That CNV
reduction induced by PlGF-1 was not enhanced by coadministration of VEGF-E suggests that cooperation between VEGFR-1 and
VEGFR-2 is not required for antiangiogenic activity (Figure 1B).
Although VEGF-E alone increased CNV volume, it was unable to
overcome the antiangiogenic effect of PlGF-1, demonstrating the
dominance of VEGFR-1 over VEGFR-2 in this context.
VEGFR-1 blockade augmented the increase in CNV induced by
VEGF-E (Figure 2A); in the setting of exogenously triggered selective VEGFR-2 signaling, endogenous VEGFR-1 activation therefore appears to function as a negative regulator of angiogenesis.
Administration of VEGF-A and CoCl2 increased CNV in Vegfr-1
tk–/– mice, results opposite of those seen in wild-type mice and supportive of a negative regulatory function for VEGFR-1 during this
angiogenic response (Figure 2B). Collectively, these data demonstrate that the suppressive effects of VEGF-A occur through active
VEGFR-1 signaling and not by its functioning as a decoy receptor
sequestering ligand from VEGFR-2.
Endogenous VEGF-A induces a zone of angiogenic inhibition. These
data may be relevant to clinical observations. Specifically, ophthalmologists have noted that there is often a single area of CNV in
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placement of laser spots at 2 different distances (∼0.75 mm and ∼1.25 mm) from an area of
preexisting laser injury performed 2 days earlier. The initial injury was placed 2 days earlier because the peak of its VEGF-A response,
which occurs 3 days after injury (25), would
occur on the day after the secondary injury,
a time point when exogenous VEGF-A injection leads to CNV suppression (Figure 1B).
CNV volume was significantly decreased in
the subsequent laser spots, more so in those
Figure 2
nearer to (53.5% ± 5.7%; P < 0.01) than farther
VEGF-A reduced CNV via VEGFR-1. (A) Anti–VEGFR-1 Ab (40 pmol), but not anti–VEGFR-2 from (31.9% ± 10.7%; P = 0.05) the preexistAb (1.7 pmol), abrogated inhibition of CNV by CoCl2, VEGF-A, and PlGF-1. *P < 0.01 coming injury sites (Figure 3, A–C). Neutralizing
pared with drug alone. Antibody against VEGFR-2 but not VEGFR-1 modestly reduced CNV
#
compared with goat IgG (40 pmol). P < 0.05 compared with goat IgG. n = 10–12 per data anti–VEGF-A antibody, but not control goat
point. (B) VEGF-A and CoCl2 reduced CNV in wild-type mice but increased it in Vegfr1 tk−/− IgG, injected on the day interv ening between
mice compared with PBS-injected fellow eyes. #P < 0.05 compared with PBS. n = 10 per data the initial and subsequent laser injuries
reversed inhibition of CNV; a lower dose (6.7
point. CoCl2, 0.77 nmol; VEGF-A, 0.1 pmol; VEGF-E, 0.11 pmol.
fmol) was required to restore normal CNV
volume in the distant laser spots and a highpatients with AMD despite widespread disease, that is, thickening er dose (13.3 fmol) for the spots closer to the preexisting injury
of the inner aspect of Bruch’s membrane throughout the RPE and (Figure 3D). This is consistent with the notion that diffusion of
choroid (N.M. Bressler and W.F. Mieler, personal communication). VEGF-A from the original injury suppresses CNV in subsequent
Even when multiple foci exist, typically the ingrowth channels of lesions. When laser spots were placed 2 weeks after initial injury,
CNV through Bruch membrane are separated by 1 to 2 mm, with there was no significant CNV inhibition (P > 0.34) (Figure 3C),
several intervening fractures in Bruch membrane not containing consistent with absence of excess VEGF-A at this time point (25).
CNV (H.E. Grossniklaus and G.A. Lutty, personal communica- These data not only provide a mechanistic basis for the clinical
tion). Interestingly, therapeutic destruction of CNV nearly always observations but also provide insight into why anti–VEGF-A therresults in recurrence in the immediate vicinity. We speculated that apies do not maintain the short-term success seen in patients with
these phenomena result from high levels of VEGF-A emanating CNV and why they exhibit an inverse dose-response curve (15).
from the existing focus of CNV and that
these excessive amounts create a “zone of
inhibition” that suppresses formation of
adjacent CNV.
We tested to determine whether a similar
zone of inhibition exists in the mouse by
Figure 3
Preexisting CNV inhibited subsequent CNV
via VEGF-A. (A and B) Representative choroidal flat mounts show that CNV lesions (insets
show magnified images) were smaller in eyes
(A) where preexisting laser injury (area denoted by arrow) was performed 2 days earlier
compared with those in eyes (B) without prior
injury. Arrowheads denote optic nerve. Scale
bars: 200 μm. (C) Preexisting laser injury created 2 days before subsequent injury markedly decreased CNV in the subsequent laser
spots near (∼0.75 mm) the preexisting injury
and slightly decreased CNV in spots far (∼1.25
mm) from it. Preexisting laser injury created
14 days before subsequent injury in wildtype mice did not affect CNV of subsequent
laser spots either near or far from preexisting
injury. *P < 0.01 compared with eyes without
preexisting injury; #P < 0.05 compared with far
lesions in the day 2 group. n = 12 per data
point. (D) Neutralizing anti–VEGF-A antibody
reversed this inhibition in a dose-dependent
manner. #P < 0.05 compared with no injection.
n = 12 per data point. (C and D).
424
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Figure 4
VEGF-A decreased CNV through VEGFR-1–induced
negative transduction of VEGFR-2 via SHP-1. (A)
Representative figure shows VEGFR-1 phosphorylation levels in RPE/choroid of eyes before injury (control) and 30 minutes after intravitreous injection of PBS
or VEGF-A, 1 day after injury. n = 5. WB, Western
blot. (B) Representative figure shows that VEGF-A,
injected 1 day after laser injury, increased interaction of SHP-1 with VEGFR-2 and reduced VEGFR-2
phosphorylation at 30 minutes after injection, 1 day
after injury, and before injury (control), without affecting VEGFR-2 expression. Densitometric ratios of
SHP-1 to total VEGFR-2 and of phosphorylated (P)
to total (T) VEGFR-1 or VEGFR-2 are shown before
(control) and after injury. Ratios were normalized to
control values. n = 5. (C) VEGF-A–induced CNV suppression was abrogated by BMOV (0.16 μmol) and
sodium stibogluconate (SSG) (0.56 nmol) in wild-type
mice. n = 12 per data point. (D) VEGF-A did not significantly suppress CNV in Shp1–/– mice (n = 12 per
data point; P = 0.44). *P < 0.05 compared with PBS.
VEGF-A, 0.1 pmol.

VEGF-A ligation of VEGFR-1 negatively regulates VEGFR-2 signaling
via SHP-1. We studied whether VEGF-A executes its antiangiogenic
program by directly promoting VEGFR-1 activity or antagonizing
VEGFR-2 activity. VEGFR-1 tyrosine kinase phosphorylation was
markedly enhanced following injection of VEGF-A 1 day after laser
injury (Figure 4A). Simultaneously, we observed increased interaction between the protein tyrosine phosphatase (PTP) Src homology
domain 2–containing (SH2-containing) tyrosine phosphatase-1
(SHP-1) and the VEGFR-2 complex as well as a reduction in VEGFR-2
phosphorylation (Figure 4B). These findings are compatible with a
model in which VEGFR-1 negatively regulates VEGFR-2 activation via
SHP-1, although conclusive evidence of a direct effect awaits development of a VEGFR-1–specific tyrosine kinase inhibitor. We confirmed
that VEGFR-2 dephosphorylation translated into a functional inhibition of angiogenesis because the pan-PTP inhibitor bis(maltolato)
oxovanadium(IV) (BMOV) abrogated VEGF-A–induced inhibition of
CNV (Figure 4C). Sodium stibogluconate, a potent SHP-1 inhibitor
(26), also reversed VEGF-A–induced inhibition of CNV (Figure 4C).
Further, we demonstrated that Shp1–/– mice were resistant to VEGF-A–
induced CNV suppression (Figure 4D). Collectively, these data confirm a specific effect of VEGF-A on SHP-1. We also observed that
VEGF-A did not modulate the interaction between VEGFR-2 and
other PTPs, such as PTP1B and human low molecular weight cytoplasmic PTP (HCPTPA) (data not shown). These data demonstrate that,
after laser injury, excess VEGF-A negatively regulates VEGFR-2 signaling and identify a potentially novel mechanism by which VEGF-A
can modulate its own angiogenic action.
SPARC regulates VEGF-A-induced effects on CNV. In contrast to their
antiangiogenic action when injected after laser injury, VEGF-A
and CoCl2 increased CNV when injected 1 day before injury (Figure 5). This was mediated via VEGFR-2 signaling because VEGF-E,
but not PlGF-1, promoted CNV when injected 1 day before injury
(Figure 5). In most tissues, VEGFR-1 autophosphorylation was
weak, possibly because it is constitutively repressed. Therefore, we
postulated the presence of a protein that would restrain VEGFR-1
kinase at rest and would itself be diminished after injury, thereby
relieving the functional block of VEGFR-1 activation.

One such candidate is SPARC, which we previously demonstrated binds to VEGF-A and inhibits the kinase activity of VEGFR-1
but not VEGFR-2 in vitro (17). SPARC was constitutively expressed
in the RPE/choroid, but its expression declined after injury and
recovered to near-baseline levels 2 days later (Figure 6A). We also
identified a specific binding interaction between SPARC and
VEGF-A in the mouse eye in vivo (Figure 6B); this interaction was
specific because VEGF-A was not bound to IGF-binding protein-3
(IGFBP-3), a matricellular protein like SPARC (Figure 6C). Suppression of CNV induced by VEGF-A injected 1 day after injury,
when levels of SPARC were declining, was dose dependently abolished by recombinant human SPARC (2.5–7.5 pmol), which is
92% identical to mouse SPARC (Figure 6D) (27). Restoration of
CNV by exogenous SPARC was essentially eliminated by a neutralizing antibody against SPARC, confirming the specificity of this
response (Figure 6D). The anti-SPARC IgG (26.7–80 pmol) inhibited the augmented CNV resulting from VEGF-A injected 1 day
before injury, when SPARC levels were high (Figure 6E).

Figure 5
VEGF-A increased CNV before injury via VEGFR-2. Injected 1 day
before injury, VEGF-A (0.1 pmol), VEGF-E (0.11 pmol), and CoCl2
(0.77 nmol), but not PlGF-1 (43.1 pmol), increased CNV. *P < 0.05
compared with PBS. n = 10 per data point.
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Figure 6
SPARC regulated VEGF-A effects on CNV. (A) Constitutive (control) RPE/choroid expression of SPARC was decreased 1 day after laser injury
and recovered 2 days after injury. Figure is representative of 3 experiments. (B and C) Immunoprecipitation of 3 independent samples revealed
that VEGF-A interacted with SPARC (B) but not IGF binding protein-3 (IGFBP-3) (C) in vivo. (D) CNV inhibition by VEGF-A injected 1 day after
injury was abolished by recombinant human SPARC (rhSPARC) and restored by neutralizing anti-SPARC Ab (80 pmol). *P < 0.05 compared with
PBS. Recombinant SPARC injection alone (white bar) did not change CNV compared with PBS. (E) Neutralizing anti-SPARC Ab (26.7 pmol) but
not control mouse IgG abrogated CNV increase induced by VEGF-A 1 day before injury. *P < 0.05 compared with PBS. (F) VEGF-A injected 1
day before laser injury increased CNV in SPARC+/+ mice but not in SPARC–/– mice. VEGF-A injected 1 day after laser injury decreased CNV in
SPARC+/+ and SPARC–/– mice. *P < 0.05 compared with PBS injection on the same day. VEGF-A, 0.1 pmol. n = 10–14 per data point (D–F).

The pro- and antiangiogenic actions of VEGF-A injected before
versus after injury, respectively, were duplicated in Sparc+/+ mice.
However, in Sparc–/– mice, the proangiogenic response of VEGF-A
injected 1 day before injury was eliminated, whereas the antiangiogenic response of VEGF-A injected 1 day after injury was preserved
(Figure 6F). Of note, the basal CNV response in Sparc–/– eyes was
modestly but significantly greater than in Sparc+/+ eyes, consistent
with the diminished ECM characteristic of Sparc–/– mice that has
been proposed as permissive for enhanced tumor growth (28).
The modest difference between Sparc+/+ mice and C57BL/6J mice
in basal CNV response is attributed to the genetic variation arising from their mixed background. Collectively, these data indicate
that SPARC limits the capacity of excess VEGF-A to suppress CNV
via VEGFR-1 and that the transient decline of SPARC in the wake
of injury unmasks the antiangiogenic action of VEGF-A due to
unsilencing of VEGFR-1 activation.
Discussion
Historically, VEGFR-1 was assigned a role as a nonsignaling decoy
receptor because of the low activity and embryonic dispensability
of its tyrosine kinase function. More recently, its role has become
more interesting because VEGFR-1 signaling has been reported
both to promote (6, 7) and suppress (8) VEGF-A–driven angiogenesis. We report not only that PlGF-1 inhibits inflammatory CNV,
extending the scope of VEGFR-1 function, but also what we believe
is the unprecedented observation that VEGF-A itself can suppress
angiogenesis. Multiple lines of evidence emerging from genetic
ablation, antibody neutralization, and receptor-selective ligand
activation all strongly support the thesis that the antiangiogenic
action of VEGF-A is mediated by VEGFR-1. Previously, VEGF-A
has been reported to reduce VEGF-E–induced VEGFR-2 tyrosine
kinase phosphorylation in capillary endothelial cells in vitro, raising the provocative hypothesis that VEGF-A could limit its own
426

angiogenic activity through VEGFR-1 (29). We have presented in
vivo confirmation of this hypothesis. These findings contribute
significantly to our understanding of the consequences of the
interaction of VEGFR-1 with its ligands and describe a unique
mechanism by which VEGFR-1 regulates angiogenesis.
Prior reports have noted that the biological effects of VEGF-A are
dose dependent. These observations are consistent with our data,
which indicate that high levels of VEGF-A cannot sustain, and
indeed may inhibit, CNV. Exogenous VEGF-A in the myocardium
or skeletal muscle can lead to dysregulated vasculogenesis (30, 31)
and disrupt embryonic intersomitic artery formation (32). In addition, exogenous VEGF-A can inhibit smooth muscle cell proliferation, without affecting angiogenesis (33, 34). However, we believe
our data are the first to demonstrate direct arrest of endothelial cell
proliferation and frank inhibition of angiogenesis by VEGF-A.
These data do not contradict the well-described angiogenic properties of VEGF-A. Indeed, our data indicating that intravitreous
injection of antibodies against VEGF-A or VEGFR-2 reduces laserinduced CNV confirm findings of other investigators using different antagonists (11, 23). Rather, they unveil an unrecognized ability
of excess VEGF-A in the postinjury setting to suppress angiogenesis
by predominantly activating VEGFR-1 signaling and preventing
endothelial cells from responding to mitogenic signals. It appears
that the system is exquisitely sensitive to the precise level of VEGF-A
in the immediate postinjury period and responds differently if that
level exceeds the concentration of VEGF-A induced by injury. The
“switch” that diverts the injured tissue away from proliferation is
driven through VEGFR-1 signaling, which appears to be dominant
in an environment of excess VEGF-A, in contrast to the usual dominance of VEGFR-2. Unraveling this antagonistic pathway of excess
VEGF-A and comparing it with those of existing angiogenic inhibitors may reveal additional robust and powerful therapeutic targets
in the panoply of angiogenesis-driven disorders.

The Journal of Clinical Investigation    http://www.jci.org    Volume 116    Number 2    February 2006

Downloaded October 30, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI26316.

research article
Rakic and colleagues demonstrated that systemic administration
of anti–VEGFR-1 antibody inhibits experimental CNV (24), while
we found that intravitreous delivery did not. This divergence could
arise from the fact that cell populations are affected differentially by
local versus systemic VEGFR-1 blockade. Systemic but not intravitreous VEGFR-1 blockade would interfere with mobilization of bone
marrow–derived progenitor cells (35) that are known to contribute
to CNV (36, 37). This difference is clinically relevant as most anti–
VEGF-A therapies for CNV rely on intravitreous delivery to minimize potential adverse effects of systemic VEGF-A antagonism.
Rakic et al. (24) also demonstrated that laser-induced CNV is
inhibited in Plg f –/– mice, which is consistent with the role of PlGF
in the bone marrow, where it mobilizes progenitors either directly by recruiting VEGFR-1+ cells or indirectly by inducing matrix
metalloproteinase-9, which increases progenitor cell proliferation
and motility via release of soluble Kit ligand (35). In contrast, intravitreous injection of PlGF, which inhibits CNV when administered
after injury, would not execute such effects on the bone marrow.
These differences also might have emerged because exogenous and
endogenous PlGF may heterodimerize with VEGF-A differently in
CNV. The role of these heterodimers is controversial because they
have been reported both to promote (38) and antagonize (39) neovascularization. An analogous variation is observed in experimental retinal neovascularization, which is inhibited both by genetic
ablation of Plgf (6) and by intravitreous administration of PlGF
(40), although the latter may be due to increased cell survival. A
similar divergence in angiogenic response to endogenous and
exogenous proteins exists in the case of other cytokines, such as
plasminogen activator inhibitor type I (PAI-1). Indeed, Rakic and
colleagues also have shown that laser-induced CNV is inhibited
both in Pai –/– mice and in PAI-1–treated wild-type mice (41). The
apparently different effects of endogenous and exogenous PlGF
also might reflect modulation of plasminogen activator activity
by VEGFR-1 activation (42, 43).
Reduction in CNV in Plgf –/– mice also is intriguing because these
mice express other VEGFR-1 ligands, including VEGF-A (6). This
raises the formal possibility that reduced CNV in Plgf –/– mice might
reflect molecular or developmental plasticity in response to gene
disruption rather than PlGF deficiency alone. Secondary developmental effects induced by the altered vascular phenotype account
for a similar divergence phenomenon in Alk1–/– mice, which display
enhanced angiogenesis (44), while enforced activin receptor–like
kinase 1 (ALK1) expression stimulates endothelial cell migration
and proliferation (45). It also is possible that subtle defects in ocular vascular development in Plgf –/– mice reported by Carmeliet and
colleagues (6) might have influenced their CNV responses.
These data add VEGF-A to the group of cytokines, such as
angiopoietin-1 (46–48), nitric oxide (49, 50), pigment epithelium–
derived factor (51–53), and TGF-β (45, 54), whose modulation
of angiogenesis displays context-dependent bidirectionality. The
paradoxical effect of VEGF-A resembles that of TGF-β, which is
proangiogenic at low doses and antiangiogenic at high doses, an
effect attributed to differential activation of the TGF-β receptors
ALK1 and ALK5 (45), akin to the differential routing via VEGFR-1
and VEGFR-2. This Janus-like effect reveals novel therapeutic strategies to modulate angiogenesis in the setting of inflammation and
highlights the importance of developing assays for markers such
as SPARC to target therapeutics more specifically.
In most systems, VEGFR-1 tyrosine kinase activity has been
described as weak. Our findings provide a paradigm by which

its activation is controlled in vivo by SPARC and illustrate the
multifunctional nature of this receptor in promoting or curtailing angiogenesis. These data might also explain the divergent
outcomes of experiments involving VEGFR-1 function in different angiogenesis models. The poor intrinsic kinase activity of
VEGFR-1 in many systems may be due to repressive elements in
its juxtamembrane domain (55). It is also possible that VEGFR-1
signaling could occur without phosphorylation of consensus-positive regulatory tyrosine residues, i.e., VEGFR-1 could be a poor
substrate for itself. Further investigation of the role of SPARC in
maintaining repression of VEGFR-1 may improve our fragmentary
understanding of its activation, particularly during development
and in cancer, where this receptor appears functional. In addition,
the propensity of the macula to develop CNV despite widespread
subretinal disease in AMD may be related to the concentration of
SPARC in this central region in monkeys (56) (and presumably
in humans), which may prevent downregulation of proangiogenic
VEGFR-2 signaling by VEGFR-1.
The expression and activity of SPARC are segregated largely to
tissues that are undergoing remodeling or turnover. As such, it is
well placed to regulate the activity of potent growth factors such as
VEGF-A, which often are the primary stimuli for remodeling of the
local microenvironment. The present study provides a physiological example of how SPARC potentially regulates the angiogenic
process. The initiation of angiogenesis by soluble factors such
as VEGF-A is complex and involves the activation of individual
endothelial cells that express both VEGFR-1 and VEGFR-2. Our
data point to extracellular adaptor proteins as critical linchpins in
the induction of the VEGFR-2–driven angiogenic program. Previous studies (17) showed that SPARC can interfere with VEGF-A
ligation of VEGFR-1 and that SPARC-mediated inhibition of
VEGF-A–induced phosphorylation of VEGFR-1 was long lived (at
least 24 hours). In the context of CNV, this time frame is relevant
to the demonstrated activity of VEGF-A in that setting. Investigations using mice with a deficiency in a matricellular protein
(e.g., thrombospondin-1 and/or -2, the SPARC ortholog hevin, or
SPARC) support the hypothesis that the function of matricellular proteins is contextual and that regulated expression of these
proteins is important for maintenance of tissue homeostasis and
responses to injury (16, 57, 58).
The basal CNV response of Sparc –/– mice was greater than that
of wild-type counterparts (Figure 6D), a result consistent with the
heightened neovascular response in sponge implants reported in
Sparc –/– animals as well as the synergistic increase in vascularization
in the foreign body response of SPARC/hevin double-null mice
(59, 60). The inhibitory effect of SPARC on vessel growth resides in
part in the C terminal, Ca+2-binding EF hand, whereas other peptides released by plasmin or stromelysin-1 stimulate angiogenesis
by affecting the cell cycle and/or migration of endothelial cells (27,
61). Our present study emphasizes the contextual dependence of
SPARC and its activity as a regulator of angiogenesis.
Our data define a previously unrecognized autoregulatory potential of excess VEGF-A and are relevant to ongoing clinical trials examining anti–VEGF-A therapy in AMD and VEGF-A over-expression in
ischemic limb and cardiac disease. Data from the pegaptanib clinical trials in patients with AMD showed an inverse therapeutic dose
response (15), indicating that partial inhibition of VEGF-A could be
optimal. The inability of this drug to arrest the increasing size of the
CNV lesion with time in patients with AMD indicates that VEGF-A
might have dual actions in the human eye as well. However, that
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pegaptanib decreased the rate of vascular leakage points to a divergent response of VEGF-A in mediating growth versus hyperpermeability of new blood vessels. Whether similar bifurcation of VEGF-A
signaling occurs in laser-induced CNV warrants investigation.
Our findings provide insight into the context and stage dependency of the role of VEGF-A in ocular neovascularization as well as
interactions between a matricellular protein and a VEGF receptor
that regulate and route signaling by VEGF-A. Our findings also
demonstrate alternative pathways of VEGF-A signal transduction
and emphasize the need to clarify the complex effects of interactions among VEGF-A, its receptors, SPARC, and the chemokine
network in ocular neovascularization before VEGF-A alone can be
considered an ideal therapeutic target.
Methods
Animals. Wild-type C57BL/6 mice were purchased from Jackson Laboratory. Vegfr-1 tk–/– mice were generated as described previously (5) and backcrossed 6–10 times to C57BL/6 animals. Sparc–/– and Sparc+/+ mice on a
mixed C57BL/6 × 129/SvJ background have been described (62). Mice
(6- to 8-week-old males) were anesthetized by intraperitoneal injection of
ketamine (50 mg/kg; Fort Dodge Animal Health) and xylazine (10 mg/kg;
Phoenix Scientific Inc.), and pupils were dilated with topical tropicamide
(1%; Alcon). Experiments were approved by the University of Kentucky
Institutional Animal Care and Use Committee.
CNV. Laser photocoagulation (532 nm, 200 mW, 100 ms, 75 μm) (OcuLight GL; IRIDEX Corp.) was performed on both eyes (3 spots per eye)
of each animal to induce CNV as described (25, 63). CNV volumes were
measured by scanning laser confocal microscope (TCS SP; Leica) as reported (25, 63), with 0.5% FITC-conjugated Griffonia simplicifolia isolectin B4
(Vector Laboratories) or 0.5% FITC-conjugated rat anti-mouse CD31 (BD
Biosciences), or by cardiac perfusion with 5 mg/ml FITC-dextran (2 × 106
average weight; Sigma-Aldrich). Pairwise comparisons among volumes
obtained by lectin, CD31, and dextran staining were highly correlated
(r 2 > 0.90). CNV volumes per laser lesion were compared by hierarchical
logistic regression using repeated measures analysis as described (25, 63).
Results are expressed as mean ± SEM (n refers to number of animals). Type I
error not exceeding 0.05 was deemed significant.
Drug treatments. VEGF-A164 (0.02–0.95 pmol), PlGF-1 (0.03–43.1 pmol),
neutralizing goat antibodies against (a) mouse VEGF-A (6.7–13.3 fmol),
(b) mouse VEGFR-1 (6.7–40 pmol), (c) mouse VEGFR-2 (0.17–1.7 pmol;
all R&D Systems); CoCl2 (0.77 nmol; Sigma-Aldrich), recombinant human
SPARC (64) (2.5–7.5 pmol), neutralizing mouse antibody against human
SPARC (65) (clone 293; 26.7–80 pmol; cross-reactive with mouse SPARC),
VEGF-E (0.11–1.14 pmol; Cell Sciences), BMOV (0.16 μmol; gift of J.H.
McNeill and C. Orvig, University of British Columbia, Vancouver, Canada),
or sodium stibogluconate (SSG) (0.56 nmol) were dissolved in PBS (SigmaAldrich), and injected into the vitreous cavity in a total volume of 1 μl with
a 33-gauge Exmire microsyringe (Ito Corp.).
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Western blotting. Equal amounts of total protein from RPE/choroid were
resolved on SDS 4–20% polyacrylamide gradient gels and transferred to
nitrocellulose membranes for Western blotting with goat antibody against
mouse SPARC (1:500; R&D Systems). Loading was assessed by blotting
with rabbit antibody against human GAPDH (1:2,000; Abcam).
Immunoprecipitation and immunoblotting. RPE/choroid lysates were
immunoprecipitated with goat antibodies against mouse VEGFR-1 or
VEGFR-2 (8 μg/ml; R&D Systems) that were immobilized on protein
G-agarose, subjected to SDS-PAGE, immunoblotted with mouse monoclonal antibody against phosphotyrosine (1:1,000; Upstate USA Inc.), and
subsequently reprobed with rabbit antibodies against human VEGFR-1 or
mouse VEGFR-2 (1:500; Santa Cruz Biotechnology Inc.). SPARC–VEGF-A
interaction was identified by immunoprecipitation with mouse antibody against human VEGF-A (66) (clone 12D7; 4 μg/ml; cross-reactive
with mouse VEGF-A) and immunoblotting with mouse antibody against
human SPARC (clone 293; 0.75 μg/ml) or with goat antibody against
mouse IGFBP-3 (0.1 μg/ml; R&D Systems)
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